25
Participants
Start Date
October 31, 2011
Primary Completion Date
May 31, 2013
Study Completion Date
December 31, 2013
Armodafinil
Women who are eligible will receive 4 weeks of treatment with armodafinil. Armodafinil will be titrated from 50-mg/day up to 150-mg/day. For exploratory reasons only, at the end of the 4-week treatment period, participants will enter a discontinuation phase in which they will be randomized to double-blind treatment with armodafinil 150-mg/day or matching placebo for 2 weeks in a 1-to-1 ratio. No primary outcomes were studied in the discontinuation phase.
Massachusetts General Hospital, Boston
Teva Pharmaceuticals USA
INDUSTRY
Massachusetts General Hospital
OTHER